杨宁介入医学网

Immune checkpoint inhibitorbased combinations have changed the treatment paradigm for advanced HCC [59,60] and are likely to remain the cornerstone of systemic treatment in the next few years. 基于免疫检查点抑制剂的联合治疗已经改变了晚期HC...

HAIC combined with radiation therapy (RT) has also been extensively investigated, particularly in subgroups of patients with PVT. HAIC联合放疗(RT)也已被广泛研究，特别是在PVT患者的亚组中。 Han et al. [ 51 ] conducted a small-scale single-ar...

HAIC has been combined with sorafenib to leverage the synergistic effects of the combination. HAIC已与索拉非尼联合使用，以利用该联合使用的协同效应。 A randomized Phase 2 trial was conducted to compare HAIC plus sorafenib with sorafenib alo...

Subcutaneous or intramuscular interferon-alpha (IFN-) has been used in combination with intravenous chemotherapy for advanced HCC to enhance antitumor activity [55]. 皮下或肌内干扰素(IFN-)已与静脉化疗联合用于晚期HCC，以增强抗肿瘤活性[ 55 ]...

肝( 窦) 前型非肝硬化门静脉高压症( non － cirrhotic portal hypertension，NCPH) 是一组预后可能较好、病因少见或复杂的门静脉系统或全身性疾病，肝脏功能基本正常、肝 静 脉 压 力 梯 度 ( hepatic venous pressure gradient，HVPG) 正常或轻度增加为特征...

肝性胸水（Hepatic hydrothorax，HH） HH is the accumulation of a significant amount of transudative fluid, usually over 500 mL, in the pleural cavity of patients with decompensated liver cirrhosis without coexisting primary cardiopulmonary...

Ascites is the most common complication of PH in cirrhosis, with approximately 60% of compensated cirrhosis patients developing the condition within ten years of diagnosis[74]. 腹水是肝硬化中PH最常见的并发症，约60%的代偿性肝硬化患者在诊断...

HRS is usually manifested in the advanced stage of cirrhosis with PH. HRS(Hepatorenal Syndrome)发生在门静脉高压肝硬化晚期。（严重肝病晚期可能出现的一种并发症） International Club of Ascites has defined HRS as an increase in serum creatinin...

并非所有复发或者重复出血的病例都适于行TIPS。禁忌证可能是技术上的或者临床上的。最常见的技术上的禁忌证是门静脉闭塞。但是，TIPS有时可以在局部门静脉闭塞的患者中成功的应用，TIPS甚至可以在慢性闭塞病人中的完成。...

从长期来看TIPS的技术缺陷是进行性的分流失效。这是为什么进行TIPS的病人必须认真随访并规律的进行开放性的评价。大多数中心使用3月间隔为最小期限来进行临床和Doppler检查。在这样的计划中，长期随访显示了由于分流失效而造成的再出血减少到少于5％，可以诊...